Refractory AML Clinical Trial
Official title:
A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06007911 -
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT06316960 -
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
|
Phase 2 | |
| Recruiting |
NCT06307054 -
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
|
Phase 1 | |
| Recruiting |
NCT04310592 -
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
|
Phase 1 | |
| Completed |
NCT05193448 -
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
|
||
| Recruiting |
NCT05735184 -
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
|
Phase 1 | |
| Recruiting |
NCT06022003 -
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
|
Phase 2 | |
| Active, not recruiting |
NCT04330820 -
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05226468 -
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
|
Phase 1 | |
| Terminated |
NCT03516760 -
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
|
Phase 1 |